WASHINGTON DC (June 16, 2021) – “The Association for Accessible Medicines (AAM) strongly encourages the Maine House of Representatives to oppose LD 1117. The fact is generic medicines drive cost savings for patients and increase access to life-saving treatments. According to the Maine Health Data Organization, every one of the 25 most costly prescription drugs in the state is a brand-name drug – none are generic medicines. LD 1117 misdiagnoses the problem of high drug prices and instead would only result in harming patient access to affordable generic medicines.”
Attribution: Dan Leonard, President and CEO, AAM
For more on AAM’s views on LD 1117, read blog: Generic Medicines Provide Savings for Maine Patients.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.